Skip to content
    AJU IB Investment logo

    AJU IB Investment

    Seoul, South KoreaFounded 1974
    www.ajuib.co.kr/eng/mainLinkedIn
    Biotech & Life SciencesAIHealthcareEnterprise Software

    Founded in 1974, AJU IB Investment is South Korea's first venture capital firm, providing multistage VC and PE investment to innovative companies across all stages of development, from early-stage startups to pre- and post-IPO. Headquartered in Seoul, the firm manages alternative investment funds and also operates internationally through its subsidiary Solasta Ventures.

    41% of their portfolio is in Biotech & Life Sciences. Deal activity increased 300% year-over-year (4 deals in the last 12 months). Average disclosed round size is $731.4M (across 49 rounds with reported amounts).

    Find people at AJU IB Investment on Goldilocks AI

    Portfolio

    55

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    4

    Team

    Park, Gyehoon

    Park, Gyehoon

    Managing Director

    Yang, Kwangsun

    Yang, Kwangsun

    Managing Director

    Chang, Hwanyoung

    Chang, Hwanyoung

    Associate Investment Director

    Cho, Namchun

    Cho, Namchun

    Sr. Investment Director

    Choi, SungRak

    Choi, SungRak

    Investment Director

    Choi, Yongseok

    Choi, Yongseok

    Investment Director

    Huh, Byungdoo

    Huh, Byungdoo

    Executive Director

    Jang, Yunhee

    Jang, Yunhee

    Director

    Jeon, Doyeong

    Jeon, Doyeong

    Director

    Jung, Daeseok

    Jung, Daeseok

    Executive Director

    KJ

    Kang, Jiyoong

    Investment Director

    Kim, Seunghyeon

    Kim, Seunghyeon

    Investment Director

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    86 investments
    CompanyRoundAmountDate
    EEnventricIpo—Jun 2026
    Twinny logoTwinnyUnknown—Jan 2026
    Cenyx Biotech logoCenyx BiotechSeed—Jan 2026
    WearLinQ logoWearLinQSeries A$14MDec 2025
    Nex-i logoNex-iSeries B—Aug 2025
    Illimis Therapeutics logoIllimis TherapeuticsSeries B—Jul 2025
    SSelvaticoSeries A—Jan 2025
    IM Biologics logoIM BiologicsIpo$28.7MJan 2025
    Nex-i logoNex-iUnknown—Jan 2025
    MMBDIpo—Jan 2025
    NNEX-I, Inc.Unknown—Jan 2025
    DeepX logoDeepXSeries C$80MMay 2024
    Kristin Company logoKristin CompanySeries A—Nov 2023
    Mezoo logoMezooUnknown—Nov 2023
    JJNPMEDI INC.Series A$10.3MJan 2023
    IM Biologics logoIM BiologicsSeries B$2.0MJan 2023
    Onconic Therapeutics logoOnconic TherapeuticsSeries B$19.9MDec 2022
    BoostImmune logoBoostImmuneSeries A—Jun 2022
    Onconic Therapeutics logoOnconic TherapeuticsUnknown—Jan 2022
    JNP Medi logoJNP MediSeries A$10.3MJan 2022
    SodaCrew logoSodaCrewSeries B$4.1MJan 2022
    Wave logoWaveSeries A$200MSep 2021
    SS-alpha TherapeuticsSeed$8.7MJul 2021
    SS Alpha TherapeuticsSeed$8.7MJul 2021
    IM Biologics logoIM BiologicsSeries A$2.0MJan 2021
    Page 1 of 4

    Top Co-Investors

    DSC Investment7 shared
    Korea Development Bank6 shared
    Stonebridge Partners6 shared
    LB Investment4 shared
    IMM Investment4 shared
    Shinhan Capital4 shared
    RA Capital Management4 shared
    Amgen Ventures4 shared
    Atinum Investment4 shared
    Industrial Bank of Korea4 shared
    Korea Investment Partners4 shared
    Premier Partners4 shared
    MRL Ventures Fund3 shared
    Sanofi Ventures3 shared
    Pfizer Ventures3 shared
    Intel Capital3 shared
    FuturePlay3 shared
    Solasta Ventures3 shared
    Alta Partners3 shared
    CJ Investment3 shared

    Last updated: 8 September 2026